Top Markets
Coin of the day
Inventiva S.A. Inventiva S.A.

Inventiva S.A.

IVA
株式のランク #8990
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
株価
$4.74
最終同期: 2026-08-28
時価総額
$1.12B
変化(1日)
-5.77%
変化(1年)
-16.96%
FR
取引 Inventiva S.A. (IVA)

カテゴリー

Inventiva S.A.(IVA)のEPS
2026 時点のEPS TTM: 0
Inventiva S.A.の最新の財務報告と株価によると、同社の現在のEPS(TTM)は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Inventiva S.A.のEPS履歴(2026から2026まで)
各年末時点のEPS
EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS
企業 EPS EPSの差
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH